Mediacast
- Uncharted Waters
-
Sandy Hillsberg, managing partner with Los Angeles-based law firm TroyGould, discusses how the global financial crisis is affecting emerging biotechnology companies.
- Harnessing Science
-
Dr. Louis Renzetti, vice president and global head of RNA therapeutics at Roche, explains the enormous potential of RNAi technology in the development of new medicines.
- A Common Path
-
Dr. Christian Weyer, vice president of clinical research at Amylin Pharmaceuticals, Inc. explains how the company’s current obesity therapy trials grew out of its diabetes program.
- Peaks and Valleys
-
Dr. Mario Raviglione, director of the Stop TB Department at the World Health Organization, outlines the successes and set backs in the global effort to end tuberculosis.
- BIOspeak
-
Jim Greenwood, president and CEO of the Biotechnology Industry Organization (BIO), discusses the most pressing policy challenges facing the industry today.
- A New Gold Standard
-
John Doyle, DrPH, practice leader for market access at Quintiles Consulting, discusses the concept of a health economic balance sheet and the need for evidence-based pricing for biopharmaceutical valuation.
- A Shot in the Arm
-
Darrick Carter, Ph.D., director of formulations for the Infectious Disease Research Institute, discusses the numerous public/private partnerships involved in developing more effective vaccines for neglected diseases.
- Informed Choices
-
Dr. Scott Gottlieb, resident fellow at the American Enterprise Institute, explains how pharma’s future is dependent on sound public policy.
- Untapped Potential
-
Dr. Alessio Fasano of the University of Maryland School of Medicine talks about current research into the treatment and management of celiac disease.
- Innovation Through Collaboration
-
Joseph McCracken, vice president of business development at Genentech, discusses his company’s partnering philosophy.
Web Exclusives
- Measure for Measure
-
A proposed Health Care Comparative Effectiveness Research Institute in the United States may force the biopharmaceutical industry to emphasize patient outcomes and quality of life issues when developing a new medicinal product.
- Evidence-Based Development and Smarter Sourcing
-
Jay Norman, president of Quintiles Consulting, discusses the changing landscape of drug development and suggests that better, evidence-based decisions, combined with smart sourcing strategies, will differentiate the future winners.